Evotec (EVO) Q2 2026: Revenue Guidance Cut by Up to 22% Amid Strategic Partnership Timing Shifts
Evotec’s updated outlook reflects a significant downward revision driven by delayed milestone revenues and slower-than-expected strategic partnership contributions, despite strengthening base CRO and CDMO sales momentum. The company’s transformation program progresses with cost savings on track, but revenue conversion timing remains a critical challenge. Investors should monitor the pipeline conversion pace and commercial execution improvements as key drivers for 2027 recovery.
Summary
- Strategic Partnership Timing Disruption: Delays in milestone recognition and new agreements push substantial revenue into 2027.
- Base Business Momentum Strengthens: Discovery & Preclinical Development net sales grow 28% year-over-year, signaling improving customer engagement.
- Transformation and Cost Discipline: Horizon program advances with expected 20-30% of €75 million annual savings realized in 2026.
Business Overview
Evotec SE is a life sciences company specializing in drug discovery and development services, operating primarily through two segments: Discovery & Preclinical Development (D&PD), which provides research services and integrated programs, and Just – Evotec Biologics (JEB), focusing on biologics development and manufacturing, including continuous bioprocessing. The company generates revenue from standalone scientific services, integrated programs, and complex strategic partnerships involving milestone payments and long-term collaborations.
Performance Analysis
Evotec reported preliminary unaudited Group revenues of approximately €300.1 million for the first half of 2026, reflecting a 19% decline year-over-year. The D&PD segment accounted for €227.9 million, down 16%, while JEB revenues decreased 29% to €72.3 million. The adjusted Group EBITDA was negative €42.7 million, pressured by lower-than-expected milestone revenues and ongoing investments in transformation initiatives.
The company revised its full-year 2026 revenue guidance to €570-610 million, down from €700-780 million previously, representing a reduction of up to 22%. Adjusted EBITDA guidance was also lowered to a range of negative €70 to negative €105 million. Key drivers of the revision include approximately 40% of the revenue gap due to delayed milestone recognition from existing partnerships, 45% attributable to slower-than-anticipated new strategic partnership contributions, and 15% related to lower sales-to-revenue conversion rates.
- Revenue Phasing Impact: Milestone payments from strategic partnerships have shifted into 2027, delaying high-margin revenue recognition.
- Commercial Momentum in Base Business: Excluding strategic partnerships, D&PD net sales increased by 28% year-over-year in H1 2026, reflecting improved customer engagement and proposal activity.
- Foreign Exchange Headwinds: Unfavorable currency movements, particularly from the US dollar and British pound, reduced H1 2026 revenues by approximately €13 million.
Despite the top-line pressures, Evotec’s liquidity position improved to €465.6 million as of June 30, 2026, supported by capital raises and proceeds from portfolio company transactions. Cost savings from the Horizon transformation program are progressing as planned, expected to deliver 20-30% of the targeted €75 million annual run-rate savings by year-end.
Executive Commentary
"The number and value of partnerships we are pursuing has not changed substantially. However, the conversion of these opportunities will take longer than expected. Leading commercial indicators in the first half of 2026 document encouraging increased activity across our base DMPD business, including strengthening customer engagement and growing net sales."
Christian Wojczewski, Chief Executive Officer
"Our new outlook reflects primarily an updated view on strategic partnership activities and milestone contributions in the second half of this year. As these revenues typically carry a higher margin profile, the impact on adjusted EBITDA is expected to be disproportionate. In response, we remain focused on disciplined cash management, optimizing our cost base and reviewing our footprint capacity."
Claire Hinshelwood, Chief Financial Officer
Strategic Positioning
1. Strategic Partnership Pipeline and Timing
Evotec maintains a robust pipeline of 10 to 20 strategic partnership opportunities across key therapeutic areas such as obesity, oncology, renal disease, and women’s health. Approximately 15% of these are in late-stage negotiations expected to close by year-end, though with minimal 2026 revenue impact. The majority (around 60%) are in early to late term sheet discussions, with the remainder in due diligence. The company emphasizes that revenue delays reflect timing, not diminished conviction in these partnerships.
2. Base Business Growth and Commercial Execution
Ignoring large strategic partnerships, the D&PD segment’s base business demonstrated a 28% increase in net sales for H1 2026 compared to H1 2025. This growth is supported by a 30% rise in inbound inquiries and a 45% increase in proposals, signaling strengthening demand. The company has shortened the average sales cycle by over 15%, aiming to accelerate revenue conversion in standalone and integrated program services.
3. Just – Evotec Biologics Expansion
JEB continues to operate at high capacity with an expanding customer base. The recent launch of the J-Train offering provides customers with a turnkey continuous manufacturing solution, potentially accelerating biologics development timelines and cost efficiency. While J-Train is a strategic offering requiring longer sales cycles, it represents a new revenue and profitability stream complementing existing CDMO services.
4. Horizon Transformation and Cost Discipline
The Horizon program targets €75 million in annual run-rate cost savings by the end of 2027, with 20-30% expected to be realized in 2026. These savings focus on operational excellence, scientific leadership, and commercial execution improvements. Leadership highlights continued progress in streamlining operations and enhancing agility, which will underpin sustainable profitability as revenue conversion improves.
5. Leadership Team Strengthening
Recent leadership appointments, including a new Chief Commercial Officer, Chief Operating Officer, and CFO, bolster Evotec’s capabilities to drive commercial momentum and operational discipline. The supervisory board also received new members with deep pharmaceutical and biotech experience, reinforcing governance as the company advances its transformation and strategic partnership objectives.
Key Considerations
Evotec’s revised guidance and operational updates reflect a complex interplay of timing delays, market conditions, and strategic execution:
- Timing vs. Lost Revenue: The majority of revenue shortfall is due to timing shifts rather than lost deals, implying potential upside in 2027.
- Sales-to-Revenue Conversion Lag: Despite strong sales pipeline activity, revenue recognition lags due to contract complexity and delivery timelines.
- Strategic Partnership Complexity: Long negotiation and execution cycles for large partnerships require patient capital and operational focus.
- Cost Base Management: High fixed costs amplify EBITDA impact from revenue delays, underscoring the importance of Horizon cost savings.
- Foreign Exchange Exposure: Currency fluctuations add additional headwinds to reported revenues and margins.
Risks
Evotec faces risks from extended timelines for strategic partnership closures and milestone payments, which could further delay revenue recognition. The high fixed cost structure increases vulnerability to revenue volatility. Competitive pressures in drug discovery and biologics manufacturing markets, along with macroeconomic uncertainty affecting partner investment decisions, may also impact future performance.
Forward Outlook
For Q3 2026, Evotec anticipates continued revenue momentum in its base D&PD business but limited contribution from new strategic partnerships. The company expects to realize 20-30% of its Horizon cost savings target during 2026, improving adjusted EBITDA progressively.
- Full-year 2026 revenue guidance revised to €570-610 million (constant exchange rates: €595-635 million)
- Adjusted EBITDA expected between negative €70 and negative €105 million (constant exchange rates: negative €60 to negative €90 million)
Management emphasizes that strategic partnership deals currently under negotiation are unlikely to materially impact 2026 revenues but remain confident in their long-term value and expect contributions to increase in 2027 and beyond.
Takeaways
Evotec’s Q2 2026 results highlight the challenges of timing and complexity inherent in its strategic partnership model but also reveal strengthening fundamentals in its core drug discovery and biologics manufacturing services:
- Strategic Partnership Timing Pressure: Revenue delays from milestone payments and new agreements significantly weigh on near-term results but preserve long-term pipeline value.
- Commercial Execution Gains: Improved customer engagement and shortened sales cycles in the base business indicate a foundation for revenue growth starting late 2026.
- Transformation Progress: Horizon cost savings and leadership enhancements support operational resilience amid revenue headwinds.
Conclusion
Evotec’s updated guidance reflects a cautious stance on near-term strategic partnership contributions, offset by encouraging commercial momentum and disciplined cost management. The company’s transformation journey and robust pipeline position it for recovery and growth in 2027, contingent on successful partnership conversions and sustained execution improvements.
Industry Read-Through
Evotec’s experience underscores the challenges biotech service providers face in navigating complex, milestone-driven partnerships amid volatile market conditions. The lag between commercial activity and revenue recognition is a critical dynamic for investors to monitor across the contract research and biologics manufacturing sectors. Additionally, the emphasis on continuous manufacturing innovations, as exemplified by J-Train, signals a broader industry shift toward flexible, cost-efficient biologics production models. Competitors and investors should watch how strategic partnership pipelines convert in coming quarters as a bellwether for sector recovery and growth.